Brief: Takeda Announces US Availability Of GAMMAGARD LIQUID ERC, The Only Ready-To-Use Liquid Immunoglobulin Therapy With Low Immunoglobulin A Content1
22/01/2026 12:48
Jan 22 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T: TAKEDA ANNOUNCES U.S. AVAILABILITY OF GAMMAGARD LIQUID ERC, THE ONLY READY-TO-USE LIQUID IMMUNOGLOBULIN THERAPY WITH LOW IMMUNOGLOBULIN A (IGA) CONTENT1 TAKEDA PHARMACEUTICAL CO LTD - AVAILABLE IN 5 G/50 ML AND 10 G/100 ML VIALS Source text: ID:nBw3VHCCSa Further company coverage: 4502.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Takeda Pharmaceutical
See all newsTakeda launches sleep disorder pill in the US after DEA clearance removes final hurdle (updated)
Brief: Takeda's Orzeyful Available In U.S. By Prescription To Treat Narcolepsy Type 1 In Adults
Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle
Takeda Pharmaceutical Company Limited reports results for the quarter ended September 30 - Earnings Summary
Table: Takeda Pharmaceutical Company Limited -6-MTH group results (IFRS)